Valuation: Cadrenal Therapeutics, Inc.

Market Cap 3.85M 3.39M 3.21M 2.9M 5.47M 369M 5.54M 38.46M 14.8M 189M 14.47M 14.15M 606M P/E 2026 *
-0.28x
P/E 2027 * -0.36x
Enterprise Value 3.85M 3.39M 3.21M 2.9M 5.47M 369M 5.54M 38.46M 14.8M 189M 14.47M 14.15M 606M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
88.07%
Yield 2026 *
-
Yield 2027 * -
08-31 Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of Cad-1005 in Heparin-Induced Thrombocytopenia CI
08-13 Cadrenal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-03 Cadrenal Therapeutics Solidifies Multi-Indication Strategy For CAD-1005 In Cardiac Acute Critical Care CI
07-13 Cadrenal Therapeutics, Inc. Demonstrates Greater Than 25% Reduction in Thrombotic Events with CAD-1005 in Phase 2 Hit Clinical Trial CI
07-10 Cadrenal Therapeutics, Inc. Announces Resignation of James J. Ferguson III from Chief Medical Officer Role, Effective July 31, 2026 CI
07-01 Cadrenal Therapeutics Prices Private Placement for Up to $8.8 Million MT
06-29 Cadrenal Therapeutics, Inc. announced that it expects to receive $3 million in funding CI
06-29 Cadrenal Therapeutics, Inc. Announces CFO Changes CI
06-29 Cadrenal Therapeutics, Inc. Announces Board and Committee Changes CI
06-24 Cadrenal Therapeutics Announces Selection of Cad-1005 Phase 2 Study for Late-Breaking Oral Presentation At Isth Congress CI
06-18 Cadrenal Therapeutics, Inc. Plans To Submit Rare Pediatric Disease Designation Request For Tecarfarin In Kawasaki Disease CI
06-18 Cadrenal Therapeutics to Seek US FDA's Rare Pediatric Disease Designation for Tecarfarin to Treat Children With Kawasaki Disease MT
06-15 Cadrenal Therapeutics Advances Multi-Indication Strategy For CAD-1005 And Launches Phase 2a Acute Kidney Injury Clinical Plan CI
1 day-0.92%
1 week-18.18%
1 month-38.29%
3 months-67.66%
6 months-78.91%
Current year-84.07%
1 week 1.05
Extreme 1.05
1.25
1 month 1
Extreme 1
1.53
Current year 1
Extreme 1
8.96
1 year 1
Extreme 1
14.64
3 years 1
Extreme 1
32.55
5 years 1
Extreme 1
101.25
10 years 1
Extreme 1
101.25
Manager TitleAgeSince
Chief Executive Officer 61 2022-01-24
Director of Finance/CFO 61 2026-06-24
Chief Operating Officer 58 2024-02-05
Director TitleAgeSince
Director/Board Member 76 2023-01-18
Director/Board Member 78 2023-01-18
Chairman 61 2022-01-24
Date Insider Type Main position Quantity % Market Cap. Importance
6/2/26 Sell

Chief Executive Officer

-349 0.0122%
5/28/26 Sell

Chief Executive Officer

-2,989 0.1192%
5/22/26 Sell

Chief Executive Officer

-1,165 0.0465%
Change 5-day change 1-year change 3-year change Capi.($)
-0.92%-18.18%-92.19%-89.41% 3.89M
+4.16%-0.36%+49.37%+94.17% 71.53B
-0.19%+1.32%+37.20%+83.85% 60.12B
-1.51%+2.39%+9.10%+35.15% 48.85B
-0.05%+0.37%+41.54%+36.65% 44.28B
+0.38%+7.61%+339.53%+641.55% 43.83B
+0.18%+0.26%+7.41%+103.45% 41.53B
-0.67%+0.17%+7.60%+46.37% 30.13B
+4.77%+6.16%+36.77%+22.78% 27.98B
-1.29%-3.55%-20.74%+352.04% 25.25B
Average +0.49%+0.79%+41.56%+132.66% 39.35B
Weighted average by Cap. +0.80%+1.37%+60.93%+148.55%

Financials

2026 *2027 *
Net sales - -
Net income -12.6M -11.1M -10.51M -9.49M -17.89M -1.21B -18.12M -126M -48.4M -618M -47.31M -46.28M -1.98B -17.2M -15.15M -14.35M -12.96M -24.42M -1.65B -24.73M -172M -66.07M -843M -64.59M -63.18M -2.7B
Net Debt - -
Logo Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.
Employees
-
Date Price Change Volume
26-09-30 US$1.080 -0.92% 21,774
26-09-29 US$1.090 -2.68% 38,760
26-09-28 US$1.120 -2.61% 75,647
26-09-25 US$1.150 -4.17% 224,862
26-09-24 US$1.200 -9.09% 119,230
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.080USD
Average target price
14.00USD
Spread / Average Target
+1,196.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CVKD Stock